BACKGROUND: The @entity432 ( @entity432 ) showed no difference in outcomes between percutaneous coronary intervention (PCI) versus optimal medical therapy (MED) in @entity1 with persistent total occlusion of the @entity1188 3 to 28 days post- @entity583 . Whether PCI may benefit a subset of @entity1 with preservation of @entity1188 zone (IZ) viability is unknown. METHODS AND RESULTS: The @entity432 nuclear ancillary study hypothesized that (1) IZ viability influences left ventricular (LV) remodeling and that (2) PCI as compared with MED attenuates adverse remodeling in post- @entity583 @entity1 with preserved viability. Enrolled were 124 @entity432 @entity1 who underwent resting @entity1242 -enhanced technetium-99m sestamibi single-photon emission computed tomography (SPECT) before @entity432 randomization, with repeat imaging at 1 year. All images were quantitatively analyzed for @entity1188 size, IZ viability, LV volumes, and function in a core laboratory. At baseline, mean @entity1188 size was 26%    18 of the LV, mean IZ viability was 43%    8 of peak uptake, and most @entity1 (70%) had at least moderately retained IZ viability. There were no significant differences in 1-year end-diastolic or end-systolic volume change between those with severely reduced versus moderately retained IZ viability, or when compared by treatment assignment PCI versus MED. In multivariable models, increasing baseline viability independently predicted improvement in ejection fraction (P = .005). There was no interaction between IZ viability and treatment assignment for any measure of LV remodeling. CONCLUSIONS: In the contemporary era of MED, PCI of the @entity1188 compared with MED alone does not impact LV remodeling irrespective of IZ viability.

The @entity432 ( XXXX ) Viability Ancillary Study ( @entity432 -NUC): influence of @entity1188 zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1242 :: ('MESH:D005996', 'Chemical') :: ['nitroglycerin'] @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarct-related artery', 'infarct'] @entity432 :: ('MESH:D001157', 'Disease') :: ['OAT', 'Occluded Artery Trial'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']
@entity432 :: (MESH:D001157,Disease) :: ['OAT']
